Payer+Provider's Health System Review
FDA ends for now use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments
Judge clears path for discrimination lawsuit against Mount Sinai
January 24, 2022
Monoclonal antibody treatments by Regeneron and Eli Lilly proved ineffective against the omicron variant, the FDA said.
Read the full post on Forbes - Healthcare